About HER2/ERBB2

The ERBB2 gene (also known as HER2, human epidermal growth factor receptor 2) on chromosome 17q12 encodes a receptor tyrosine kinase in the EGFR family. HER2 amplification and overexpression occur in ~20% of breast cancers and are key biomarkers for targeted therapy. ERBB2 spans ~40 kb with 27 coding exons.

NCBI Gene ID: 2064 | RefSeq: NM_004448.3 | Genomic: NC_000017.11 (39688492-39728990)

HER2/ERBB2 Primer Design Challenges

  • Amplification quantification: qPCR requires reference gene co-amplification (e.g., RNaseP or TOP2A) for copy number normalization
  • GC-rich regions: Exons 1–5 contain 60–70% GC content requiring optimized parameters
  • Gene duplication: ERBB2 amplification in tumors requires primers that avoid homologous ERBB family members (EGFR, ERBB3, ERBB4)
  • Alternative transcripts: Multiple splice variants (including a constitutively active truncated form) require careful transcript selection
  • Clinical cut-offs: IHC/FISH correlation requires precise amplicon design for copy number assays

Recommended Primer Design Parameters for HER2/ERBB2

ParameterStandard ExonsGC-Rich Exons (1–5)
Primer length20-22 nt22-25 nt
GC content45-55%50-60%
Tm58-62°C60-65°C
Amplicon size150-300 bp180-350 bp
Annealing temp58-60°C62-65°C
PCR additiveStandardAdd 5% DMSO or 1M betaine

Key SNPs to Avoid in Primer Binding Sites

When designing HER2/ERBB2 primers, avoid these significant variants:

  • rs1136201 (p.Ile655Val) — Common polymorphism in transmembrane domain, associated with cancer risk
  • rs1058808 (p.Pro1170Ala) — C-terminal variant in exon 27
  • rs4252633 (p.Trp452Cys) — Extracellular domain missense variant

Clinical Validation Required
All HER2/ERBB2 primers designed with VigyanLLM are for research use only. Clinical diagnostic applications require additional wet-lab validation, Sanger sequencing confirmation, and regulatory approval before patient use.

Design HER2/ERBB2 Primers Now

Pre-configured with HER2-specific parameters. Enter exon number or genomic coordinates.

Design HER2/ERBB2 Primers →